Junru Wu1,2,3, Hamed Moheimani2,3, Shimena Li2,3, Upendra K Kar2,3, Jillian Bonaroti2,3, Richard S Miller4, Brian J Daley5, Brian G Harbrecht6, Jeffrey A Claridge7, Danielle S Gruen2,3, Herbert A Phelan8, Francis X Guyette9, Matthew D Neal2,3, Jishnu Das10, Jason L Sperry2,3, Timothy R Billiar2,3. 1. Department of Cardiology, The 3rd Xiangya Hospital, Central South University, Changsha, China. 2. Department of Surgery, University of Pittsburgh, Pittsburgh, PA. 3. Pittsburgh Trauma Research Center, Division of Trauma and Acute Care Surgery, Pittsburgh, PA. 4. Department of Surgery, JPS Health Network in Fort Worth, TX. 5. Department of Surgery, University of Tennessee Health Science Center, Knoxville, TN. 6. Department of Surgery, University of Louisville, Louisville, KY. 7. Metro Health Medical Center, Case Western Reserve University, Cleveland, OH. 8. Department of Surgery, University Medical Center-New Orleans Burn Program, New Orleans, LA. 9. Department of Emergency Medicine, Medicine, University of Pittsburgh, Pittsburgh, PA. 10. Center for Systems Immunology, Departments of Immunology and Computational & Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
OBJECTIVES: The authors sought to identify causal factors that explain the selective benefit of prehospital administration of thawed plasma (TP) in traumatic brain injury (TBI) patients using mediation analysis of a multiomic database. BACKGROUND: The Prehospital Air Medical Plasma (PAMPer) Trial showed that patients with TBI and a pronounced systemic response to injury [defined as endotype 2 (E2)], have a survival benefit from prehospital administration of TP. An interrogation of high dimensional proteomics, lipidomics and metabolomics previously demonstrated unique patterns in circulating biomarkers in patients receiving prehospital TP, suggesting that a deeper analysis could reveal causal features specific to TBI patients. METHODS: A novel proteomic database (SomaLogic Inc., aptamer-based assay, 7K platform) was generated using admission blood samples from a subset of patients (n=149) from the PAMPer Trial. This proteomic dataset was combined with previously reported metabolomic and lipidomic datasets from these same patients. A 2-step analysis was performed to identify factors that promote survival in E2-TBI patients who had received early TP. First, features were selected using both linear and multivariate-latent-factor regression analyses. Then, the selected features were entered into the causal mediation analysis. RESULTS: Causal mediation analysis of observable features identified 16 proteins and 41 lipids with a high proportion of mediated effect (>50%) to explain the survival benefit of early TP in E2-TBI patients. The multivariate latent-factor regression analyses also uncovered 5 latent clusters of features with a proportion effect >30%, many in common with the observable features. Among the observable and latent features were protease inhibitors known to inhibit activated protein C and block fibrinolysis (SERPINA5 and CPB2), a clotting factor (factor XI), as well as proteins involved in lipid transport and metabolism (APOE3 and sPLA(2)-XIIA). CONCLUSIONS: These findings suggest that severely injured patients with TBI process exogenous plasma differently than those without TBI. The beneficial effects of early TP in E2-TBI patients may be the result of improved blood clotting and the effect of brain protective factors independent of coagulation.
OBJECTIVES: The authors sought to identify causal factors that explain the selective benefit of prehospital administration of thawed plasma (TP) in traumatic brain injury (TBI) patients using mediation analysis of a multiomic database. BACKGROUND: The Prehospital Air Medical Plasma (PAMPer) Trial showed that patients with TBI and a pronounced systemic response to injury [defined as endotype 2 (E2)], have a survival benefit from prehospital administration of TP. An interrogation of high dimensional proteomics, lipidomics and metabolomics previously demonstrated unique patterns in circulating biomarkers in patients receiving prehospital TP, suggesting that a deeper analysis could reveal causal features specific to TBI patients. METHODS: A novel proteomic database (SomaLogic Inc., aptamer-based assay, 7K platform) was generated using admission blood samples from a subset of patients (n=149) from the PAMPer Trial. This proteomic dataset was combined with previously reported metabolomic and lipidomic datasets from these same patients. A 2-step analysis was performed to identify factors that promote survival in E2-TBI patients who had received early TP. First, features were selected using both linear and multivariate-latent-factor regression analyses. Then, the selected features were entered into the causal mediation analysis. RESULTS: Causal mediation analysis of observable features identified 16 proteins and 41 lipids with a high proportion of mediated effect (>50%) to explain the survival benefit of early TP in E2-TBI patients. The multivariate latent-factor regression analyses also uncovered 5 latent clusters of features with a proportion effect >30%, many in common with the observable features. Among the observable and latent features were protease inhibitors known to inhibit activated protein C and block fibrinolysis (SERPINA5 and CPB2), a clotting factor (factor XI), as well as proteins involved in lipid transport and metabolism (APOE3 and sPLA(2)-XIIA). CONCLUSIONS: These findings suggest that severely injured patients with TBI process exogenous plasma differently than those without TBI. The beneficial effects of early TP in E2-TBI patients may be the result of improved blood clotting and the effect of brain protective factors independent of coagulation.
Authors: Mariana Vigiola Cruz; Bonnie C Carney; Jenna N Luker; Kyle W Monger; Juan Sebastian Vazquez; Lauren T Moffatt; Laura S Johnson; Jeffrey W Shupp Journal: J Surg Res Date: 2018-09-22 Impact factor: 2.192
Authors: Ayesha Imam; Guang Jin; Martin Sillesen; Simone E Dekker; Ted Bambakidis; John O Hwabejire; Cecilie H Jepsen; Ihab Halaweish; Hasan B Alam Journal: J Neurotrauma Date: 2014-12-19 Impact factor: 5.269
Authors: Nicholas R Kunio; Jerome A Differding; Katherine M Watson; Ryland S Stucke; Martin A Schreiber Journal: Am J Surg Date: 2012-03-15 Impact factor: 2.565
Authors: Hunter B Moore; Ernest E Moore; Michael P Chapman; Kevin McVaney; Gary Bryskiewicz; Robert Blechar; Theresa Chin; Clay Cothren Burlew; Fredric Pieracci; F Bernadette West; Courtney D Fleming; Arsen Ghasabyan; James Chandler; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Jason M Samuels; Ernest E Moore; Christopher C Silliman; Anirban Banerjee; Mitchell J Cohen; Arsen Ghasabyan; James Chandler; Julia R Coleman; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2019-04 Impact factor: 3.313
Authors: Francis X Guyette; Joshua B Brown; Mazen S Zenati; Barbara J Early-Young; Peter W Adams; Brian J Eastridge; Raminder Nirula; Gary A Vercruysse; Terence O'Keeffe; Bellal Joseph; Louis H Alarcon; Clifton W Callaway; Brian S Zuckerbraun; Matthew D Neal; Raquel M Forsythe; Matthew R Rosengart; Timothy R Billiar; Donald M Yealy; Andrew B Peitzman; Jason L Sperry Journal: JAMA Surg Date: 2020-10-05 Impact factor: 14.766
Authors: Evan M Lutton; S Katie Farney; Allison M Andrews; Vladimir V Shuvaev; Gwo-Yu Chuang; Vladimir R Muzykantov; Servio H Ramirez Journal: Front Neurol Date: 2019-06-06 Impact factor: 4.003